Home Ingredients LuraLean® (Propolmannan Konjac Fiber — AHD International)
Weight ManagementMetabolic Health

LuraLean® (Propolmannan Konjac Fiber — AHD International)

Amorphophallus konjac
Evidence Level
Moderate
3 Clinical Trials
8 Documented Benefits
3/5 Evidence Score

LuraLean® is a uniquely refined glucomannan extract (propolmannan) from Amorphophallus Propol konjac root. Patented extraction removes mannanase (common in other konjac products) that would degrade glucomannan. Result: nearly pure fiber with higher molecular weight and viscosity — maintaining viscosity throughout the GI tract. Absorbs liquid expanding up to 200× original size in stomach for fullness. Many clinical trials document weight loss, cholesterol reduction, and blood glucose control; an 8-week study reported about 5.5 lbs weight loss alongside reductions in total and LDL cholesterol.

Studied Dose 1-3 g/day before meals with water.
Active Compound Propolmannan — refined high-viscosity glucomannan (soluble fiber) from Amorphophallus konjac root.

Benefits

5.5 lbs weight loss in 8-week clinical trial

Glucomannan supplementation produced significant mean weight loss of about 5.5 lbs (2.5 kg), with participants who consumed LuraLean prior to meals achieving greater weight loss than control. Foundation for LuraLean's weight management positioning.

Supported by Trial 1, Trial 2

Cholesterol and LDL reduction

Serum total cholesterol and LDL cholesterol were significantly reduced (about 21.7 and 15.0 mg/dL respectively) in the glucomannan-treated group vs control. Multi-parameter cardiovascular benefit alongside weight loss — addressing two major risk factors simultaneously. Particularly valuable for metabolic syndrome populations.

Supported by Trial 1

Blood glucose lowering effects

Clinical studies submitted to regulatory bodies showed LuraLean effectively reduced glucose levels. Soluble fiber consistently lowers after-meal elevations in blood glucose by slowing carbohydrate absorption. Mechanism supports both diabetic management and metabolic health applications.

Supported by Trial 2

Appetite suppression via 200× expansion

LuraLean absorbs liquid within the stomach to expand up to 200 times its original size — producing a feeling of fullness while following a reduced-calorie diet. Mechanical satiety mechanism distinguishes from neurochemical appetite suppressants. Particularly valuable for dietary compliance support.

Supported by Trial 2

Higher viscosity than generic glucomannan

LuraLean's proprietary extraction produces nearly pure fiber with higher molecular weight and viscosity than other glucomannan products. LuraLean fiber maintains viscosity throughout the GI tract — where other fibers fall apart. The viscosity advantage drives the documented superior weight loss and metabolic effects.

Supported by Trial 3, Trial 1

Mannanase removal — extended GI activity

LuraLean is produced through a 100% natural process that removes mannanase — the enzyme commonly found in other konjac/glucomannan products that limits efficacy by breaking down glucomannan before it's ingested. The mannanase-free formulation explains LuraLean's superior performance vs generic glucomannan products.

Supported by Trial 3, Trial 1

Lipid binding (fecal cholesterol excretion)

As LuraLean moves through the gastrointestinal system, it acts like a magnet to attract excess oils and calories and carry them out of the system. Mechanism involves binding bile acids and dietary cholesterol — stimulating fecal excretion of cholesterol. Explains the cholesterol-lowering effects documented in clinical trials.

Supported by Trial 1, Trial 2

Carbohydrate absorption modulation

Soluble fiber including LuraLean reduces the rate of carbohydrate absorption — flattening post-meal blood glucose spikes. Mechanism supports both diabetic blood sugar management and broader metabolic applications. Particularly relevant for high-carbohydrate diets where glucose spikes drive metabolic dysfunction.

Supported by Trial 2, Trial 3

Mechanism of action

1

Gastric expansion satiety

LuraLean absorbs water and expands up to 200 times its original size in the stomach. The mechanical gastric distension triggers satiety signals (stretch receptors, CCK release) that reduce subsequent food intake. Mechanical mechanism distinguishes from neurochemical appetite suppressants — works regardless of mood or willpower.

2

Viscosity maintenance through GI tract

LuraLean's higher molecular weight and proprietary processing maintain viscosity throughout the GI tract — where other fibers fall apart. Sustained viscosity supports continued satiety and metabolic effects throughout digestion. Explains LuraLean's superior performance vs generic glucomannan in clinical studies.

3

Bile acid sequestration

Soluble viscous fiber binds bile acids in the intestine, preventing their reabsorption. The liver compensates by using cholesterol to synthesize new bile acids — reducing serum cholesterol. Mechanism explains the documented cholesterol and LDL reductions in clinical trials.

4

Carbohydrate absorption delay

Viscous fiber slows gastric emptying and small intestinal transit — delaying carbohydrate absorption. The slower glucose entry into circulation reduces post-meal glucose spikes and insulin demand. Particularly valuable for diabetic and pre-diabetic populations.

5

Fecal fat binding

LuraLean attracts excess oils and calories and carries them out of the system — reducing caloric absorption. Combined with the satiety mechanism, supports dual approach to weight management. Note that this is a modest effect — primary weight loss mechanism is appetite/satiety, not malabsorption.

Clinical trials

1
LuraLean 8-Week Weight Loss Clinical Trial

Published 8-week clinical trial evaluating glucomannan (LuraLean form) for weight management and lipid effects. Foundation for LuraLean's commercial positioning for weight loss and cholesterol reduction. Standard intervention design with placebo comparator.

Adults seeking weight management support. 8-week intervention.

Significant mean weight loss of 5.5 lbs (2.5 kg) over 8-week period. Serum cholesterol reduced 21.7 mg/dL. LDL cholesterol reduced 15.0 mg/dL. Multi-parameter improvement addressing both weight and cardiovascular risk factors. Established LuraLean's clinical efficacy for weight management.

2
LuraLean ERSP Review — Substantiated Claims

Electronic Retailing Self-Regulation Program (ERSP) review of LuraLean-containing products. Marketers submitted multiple clinical studies on LuraLean for appetite suppression, satiety, and weight loss claim substantiation. Regulatory review supports clinical evidence base.

Various — review of multiple clinical studies submitted for claim substantiation.

Participants who consumed LuraLean prior to meals were able to achieve greater weight loss than control treatment. Other studies submitted showed LuraLean effectively reduced glucose levels. Clinical evidence supports appetite suppression and caloric absorption effects. Note: 'fat absorption' claim required modification — primary weight loss mechanism is satiety, not fat malabsorption.

3
Glucomannan Class Evidence — 60+ Clinical Trials

Class evidence base of over 60 clinical trials on glucomannan demonstrating effectiveness for weight management, blood sugar control, and cholesterol reduction. Wide variation exists between glucomannan products — LuraLean's standardized propolmannan distinguished by higher viscosity and mannanase-free formulation.

Various — extensive class evidence base for glucomannan from konjac root.

More than 60 clinical trials attest to LuraLean's and glucomannan's effectiveness. Note: not all glucomannan trials are positive — an 8-week trial in overweight/moderately obese adults found no significant weight loss difference vs placebo (NCT00613600). Variation likely reflects differences in glucomannan source, molecular weight, processing, and dose timing.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; soluble fiber with long dietary use history.
Mild GI effects possible — bloating, gas; typically resolves with continued use.
Must be taken with adequate water due to 200× expansion factor — risk of choking or esophageal obstruction if taken without sufficient fluid.
Should be taken at least 1 hour before or 2 hours after medications to avoid affecting absorption.
Long-term safety supported by konjac's traditional dietary use in Asian cuisines.
Pregnancy and lactation: dietary konjac is safe; supplemental concentrations consult clinician.
Individuals with swallowing difficulties should consult clinician before use.

Important Drug interactions

All oral medications — LuraLean may bind and reduce absorption; take medications 1+ hour before or 2+ hours after.
Diabetes medications — additive glucose-lowering effects; monitor blood glucose; may require dose adjustment.
Cholesterol medications — generally complementary; addresses cholesterol via bile acid binding.
Anticoagulants (warfarin) — fiber may affect vitamin K absorption; monitor INR.
Levothyroxine and other thyroid medications — separate timing strictly to avoid absorption interference.
Pregnancy and lactation: consult clinician.
Birth control pills — may reduce absorption; separate timing or consider non-oral methods.

More Weight Management Ingredients

Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…
Weight Management
Glucomannan (Konjac Root Fiber)
Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Am…
Weight Management
Supresa® (Saffron Extract for Appetite & Crave Control — PLT Health)
Supresa is PLT Health Solutions' patented saffron (Crocus sativus L.) stigma extract, clin…
Weight Management
Erythritol
Erythritol is a 4-carbon sugar alcohol (polyol) — about 60-70% as sweet as sucrose with es…

Explore Other Ingredients

Immune Support
Spirulina
Spirulina is a blue-green algae celebrated as a nutrient-dense superfood, packed with prot…
Metabolic Health
GlucoVantage® (Dihydroberberine)
GlucoVantage® is NNB Nutrition's patented dihydroberberine (DHB) — the active reduced meta…
Metabolic Health
Berberine
Berberine is a bioactive compound extracted from plants like barberry and goldenseal, know…

Frequently asked questions about LuraLean® (Propolmannan Konjac Fiber — AHD International)

What is LuraLean?

LuraLean® is a uniquely refined glucomannan extract (propolmannan) from Amorphophallus Propol konjac root. Patented extraction removes mannanase (common in other konjac products) that would degrade glucomannan.

What is LuraLean used for?

LuraLean is researched primarily for Weight Management and Metabolic Health. Glucomannan supplementation produced significant mean weight loss of about 5.5 lbs (2.5 kg), with participants who consumed LuraLean prior to meals achieving greater weight loss than control.

What is the recommended dosage of LuraLean?

The clinically studied dose is 1-3 g/day before meals with water. Always follow the product label and check with a healthcare provider for personal advice.

Is LuraLean safe, and does it have side effects?

For most healthy adults, LuraLean is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; soluble fiber with long dietary use history. Mild GI effects possible — bloating, gas; typically resolves with continued use. It may also interact with some medications. LuraLean is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does LuraLean interact with any medications?

Possible interactions include: All oral medications — LuraLean may bind and reduce absorption; take medications 1+ hour before or 2+ hours after. Diabetes medications — additive glucose-lowering effects; monitor blood glucose; may require dose adjustment. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for LuraLean?

NutraSmarts rates the evidence for LuraLean as Moderate (3 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sood N, Baker WL, Coleman CI Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis The American Journal of Clinical Nutrition. 2008;88(4):1167-75. doi: 10.1093/ajcn/88.4.1167.PubMedUsed to support: Meta-analysis of 14 RCTs (n=531) showing glucomannan supplementation significantly lowered total cholesterol (−19.28 mg/dL), LDL (−15.99 mg/dL), triglycerides (−11.08 mg/dL), fasting blood glucose (−7.44 mg/dL), and body weight (−0.79 kg). Supports Cholesterol and LDL reduction, Blood glucose lowering, and Weight loss benefits. On konjac glucomannan as a compound; LuraLean is a high-purity propolmannan form of the same fiber.
  2. Ho HVT, Jovanovski E, Zurbau A, Blanco Mejia S, Sievenpiper JL, Au-Yeung F, Jenkins AL, Duvnjak L, Leiter L, Vuksan V A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B The American Journal of Clinical Nutrition. 2017;105(5):1239-1247. doi: 10.3945/ajcn.116.142158.PubMedUsed to support: Meta-analysis of 12 RCTs (n=370) showing ~3 g/day konjac glucomannan produced a significant ~10% LDL cholesterol reduction (MD −0.35 mmol/L, 95% CI −0.46 to −0.25). Supports Cholesterol and LDL reduction benefit. On konjac glucomannan as a compound.
  3. Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, Brighenti F, Josse R, Leiter LA, Bruce-Thompson C Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial Diabetes Care. 1999;22(6):913-9. doi: 10.2337/diacare.22.6.913.PubMedUsed to support: Randomized controlled trial in type 2 diabetes showing konjac glucomannan significantly reduced fasting serum fructosamine (5.7%, p=0.007), improved total:HDL cholesterol ratio (10%, p=0.03), and lowered systolic blood pressure (6.9%, p=0.02). Supports Blood glucose lowering and Cholesterol reduction benefits with human RCT evidence. On the konjac glucomannan compound.
  4. Kaats GR, Bagchi D, Preuss HG Konjac Glucomannan Dietary Supplementation Causes Significant Fat Loss in Compliant Overweight Adults Journal of the American College of Nutrition. 2015;34(1):1-7. doi: 10.1080/07315724.2015.1009194.PubMedUsed to support: Controlled study of 83 overweight adults over 60 days showing that 3 g/day konjac glucomannan produced significant reductions in body weight, percentage body fat, fat mass, total cholesterol, and LDL in compliant participants without loss of lean mass or bone density. Supports 5.5 lbs weight loss and Cholesterol reduction benefits. On konjac glucomannan as a compound.